04476nam 2200517 450 991013711730332120170817211242.00-323-39566-X(CKB)3710000000776375(EBL)4621009(OCoLC)956278046(MiAaPQ)EBC4621009(EXLCZ)99371000000077637520160826h20152015 uy 0engur|n|---|||||rdacontentrdamediardacarrierManagement of Helicobacter pylori-related diseases /Akiko Shiotani, David Y. GrahamPhiladelphia, Pennsylvania :Elsevier,2015.©20151 online resource (246 p.)Gastroenterology Clinics of North America,0889-8553 ;Volume 44, Number 3"Clinics Review Articles."0-323-39565-1 Includes bibliographical references at the end of each chapters and index.Cover image; Title page; Table of Contents; Copyright Page; Contributors; Consulting Editor; Editors; Authors; Forthcoming Issues; Forthcoming Issues; Recent Issues; Foreword: Helicobacter pylori; Preface: Helicobacter pylori: New Thoughts and Practices; Diagnosis of Helicobacter pylori Infection in the Proton Pump Inhibitor Era; Key points; Introduction; Invasive tests; Serology; Summary: diagnosis of Helicobacter pylori infection in the proton pump inhibitors era; Practical Aspects in Choosing a Helicobacter pylori Therapy; Key points; Introduction; Choice of therapy; First-line regimensRescue therapyProbiotics; Summary; How to Effectively Use Bismuth Quadruple Therapy; Key points; Background; Bismuth in the era of new concepts regarding pathogenesis and treatment of peptic ulcer; Bismuth quadruple therapy for H pylori eradication; The effect of metronidazole resistance as examined by meta-analysis; Calculation of the effectiveness of bismuth quadruple therapy; Adherence (compliance) with bismuth quadruple therapy; How to make bismuth quadruple therapy more acceptable; DoxycyclineExamination of outcome in regions where bismuth quadruple therapy frequently fails (eg, Turkey and Iran)Bismuth, tetracycline, amoxicillin, proton pump inhibitors quadruple therapy; Bismuth sequential therapies; Information needed to obtain generalizable results; Issues ripe for systematic study; Proton pump inhibitors dosage; Efficient study design; Recommendations; Is There a Role for Probiotics in Helicobacter pylori Therapy?; Key points; What probiotics are; Probiotics; Probiotics as adjuvant therapy for Helicobacter pylori eradication; Probiotics as cure for Helicobacter pylori infectionSummaryMolecular Approaches to Identify Helicobacter pylori Antimicrobial Resistance; Key points; Molecular determination of Helicobacter pylori resistance to macrolides; Molecular determination of Helicobacter pylori resistance to fluoroquinolones; Molecular determination of Helicobacter pylori resistance to tetracycline; Molecular determination of Helicobacter pylori resistance to other antibiotics; When Is Endoscopic Follow-up Appropriate After Helicobacter pylori Eradication Therapy?; Key points; Introduction; Helicobacter pylori eradication; Uninvestigated and nonulcer dyspepsiaPeptic ulcerPremalignant gastric lesions and early gastric cancer; Hereditary risk for gastric cancer; Mucosa-associated lymphoid tissue lymphoma; Summary; Gastric Cancer Risk in Patients with Helicobacter pylori Infection and Following Its Eradication; Key points; Introduction; Helicobacter pylori infection is the most important determinant of gastric cancer risk; Gastric cancer risk: epidemiologic trends; Gastric cancer risk: the assessment; Gastric cancer risk in eradicated patients; Summary; Molecular Pathogenesis of Helicobacter pylori-Related Gastric Cancer; Key points; IntroductionClassifications and characterizations of gastric cancerGastroenterology clinics of North America ;Volume 44, Number 3.Helicobacter pyloriHelicobacter pylori.579.34Shiotani Akiko1370376Graham David Y.MiAaPQMiAaPQMiAaPQBOOK9910137117303321Management of Helicobacter pylori-related diseases3398677UNINA